The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma

Chest

Volumn 117, Issue 4, 2000, Pages 1128-1145

  Aboulafia, David M ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

AIDS; HIV; Pulmonary Kaposi's sarcoma

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BISEXUALITY; CLINICAL EXAMINATION; HISTOPATHOLOGY; HOMOSEXUALITY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; LUNG CARCINOGENESIS; LUNG SARCOMA; PRIORITY JOURNAL; REVIEW;

EID: 0034088801     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.4.1128     Document Type: Review

References (161)

1. 1 Hymes KD, Greene JB, Marcus A, et al. Kaposi's sarcoma in homosexual men: a report of eight cases. Lancet 1981; 2:598-608
2. 2 Centers for Disease Control. Pneumocystis carinii pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30:250-252
3. 3 Centers for Disease Control. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City, California. MMWR Morb Mortal Wkly Rep 1981; 30:305-308
4. 4 Friedman-Kein AE. Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol 1981; 5:468-471
5. 5 Heitzman ER. Pulmonary neoplastic and lymphoproliferative disease in AIDS: a review. Radiology 1990; 177:347-351
6. 6 Garay SM, Belenko M, Fazzini E, et al Pulmonary manifestations of Kaposi's sarcoma. Chest 1987; 91:39-43
7. 7 Gill PS, Akil B, Colletti P, et al. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am J Med 1989; 87:57-61
8. 8 Meduri GU, Stover DE, Lee M, et al. Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical, radiographic, and pathologic manifestations. Am J Med 1986; 81:11-18
9. 9 Cadranel JC, Kammoun S, Chevret S, et al. Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. Thorax 1994; 49:958-960
10. 10 Kaposi M. Idiopathisches multiples pigment sarkom der haut. Arch Dermatol Syphiole 1872; 4:265-273
11. 11 Taylor JF, Templeton AC, Vogel CL, et al. Kaposi's sarcoma in Uganda: a clinico-pathologic study. Int J Cancer 1971; 8:122-135
12. 12 Athale UH, Patil PS, Chintu C, et al. Influence of HIV epidemic on the incidence of Kaposi's sarcoma in Zambian children. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:96-100
13. 13 Hiesse C, Kriaa F, Rieu P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27:972-974
14. 14 Harwood AR, Osoba D, Hofstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979; 67:759-765
15. 15 Centers for Disease Control revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 1993:41(RR-17):1
16. 16 Beral V, Bull D, Darby S, et al. Risk of Kaposi's sarcoma and sexual practices associated with fecal contact in homosexual or bisexual men with AIDS. Lancet 1992; 339:632-635
17. 17 Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 1996; 10:997-1010
18. 18 Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-1869
19. 19 Moore PS, Chang Y. Detection of herpesvirus-like sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332:1181-1185
20. 20 Huang YQ, Li JJ, Kaplan MH, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995; 345:759-761
21. 21 Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 1999; 340:1863-1871
22. 22 Humphrey RW, O'Brien TR, Newcomb FM, et al. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood 1996; 88:297-301
23. 23 Bigoni B, Dolcetti R, de Lellis L, et al. Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. J Infect Dis 1996; 173:542-549
24. 24 Li JJ, Huang YQ, Friedman-Kien AE. Detection of DNA sequences of KSHV in blood, semen, KS tumor, and uninvolved skin of AIDS-KS patients [abstract]. AIDS Res Hum Retroviruses 1995; 11(suppl 1):S98
25. 25 Moore PS, Kingsley LA, Holmberg SD, et al. Kaposi's sarcoma-associated herpesvirus infection prior to the onset of Kaposi's sarcoma. AIDS 1996; 10:175-180
26. 26 Ressa G, Dorrucci M, Pezzotti P, et al. HHV-8 seropositivity and risk of developing Kaposi's sarcoma (KS) and other AIDS-related diseases among individuals with known dates of HIV seroconversion. Abstract 13310. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland
27. 27 Moore R, Keruly JC, Gallant J, Chaisson RE. Decline in morbidity and opportunistic disease with combination antiretroviral therapy. Abstract 22374. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland
28. 28 Costagliola D. Clinical manifestations of HIV infections in the era of highly active antiretroviral treatment (HAART) in France. Abstract 12345. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland
29. 29 Jones J, Hanson DL, Dworkin JW, et al. Effect of antiretroviral and other antiviral therapies on the incidence of Kaposi's sarcoma and trends in Kaposi's sarcoma. Abstract 13241. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland
30. 30 Buchbinder SP, Vittinghoff E, Colfax G, et al. Declines in AIDS incidence associated with highly active anti-retroviral therapy (HAART) are not reflected in KS and lymphoma incidence. Abstract S7. Presented at: 2nd National AIDS Malignancy Conference; April 6-8, 1998; Bethesda, MD
31. 31 Ryland M. Survival among Washington AIDS cases, 1987-1996. HIV/AIDS Quarterly Epidemiology Report, 2nd quarter, 1998; 11-13
32. 32 Wiggins CL, Aboulafia DM, Ryland LM, et al. Decline in HIV-associated Kaposi's sarcoma (KS), and non-Hodgkin's lymphoma (NLH) following the introduction of highly active antiretroviral therapy [abstract]. 3rd National AIDS Malignancy Conference. J Acquir Immune Defic Syndr 1999; 21:A15
33. 33 Little RF, Pluda JM, Feigal E, et al. The challenge of designing clinical trials for AIDS-related Kaposi's sarcoma. Oncology 1998; 12:871-883
34. 34 Pothoff G, Pohler E, Diekmann M, et al. Difficulties in the diagnosis of AIDS-associated intrapulmonary Kaposi's sarcoma. Pneumologie 1990; 44:74-77
35. 35 Kang EY, Staples CA, McGuinness G, et al. Detection and differential diagnosis of pulmonary infections and tumors in patients with AIDS: value of chest radiography versus CT. AJR Am J Roentgenol 1996; 166:15-19
36. 36 Stover DE, White DA, Romano PA, et al. Spectrum of pulmonary diseases associated with acquired immune deficiency syndrome. Am J Med 1985; 78:429-437
37. 37 Dail DH. Introduction to AIDS pathology in pulmonary pathology. 2nd ed. In: Dail DH, Hammer SP, eds. New York, NY: Springer-Verlag, 1994; 121-153
38. 38 Welch K, Finkbeiner W, Alpers CE. Autopsy findings in the acquired immune deficiency syndrome. JAMA 1984; 252: 1152-1159
39. 39 Lemlich G, Schwam L, Lebwhol M. Kaposi's sarcoma in acquired immunodeficiency syndrome: postmortem findings in twenty-four cases. J Am Acad Dermatol 1987; 16:319-325
40. 40 Miller RF, Tomlinson NC, Cottrill CP, et al. Bronchopulmonary Kaposi's sarcoma in patients with AIDS. Thorax 1992; 47:721-725
41. 41 Mitchell DM, McCarthy M, Fleming J, et al. Bronchopulmonary Kaposi's sarcoma in patients with AIDS. Thorax 1992; 47:726-729
42. 42 Zibrak JD, Silvestri RC, Costello P, et al. Bronchoscopic and radiologic features of Kaposi's sarcoma involving the respiratory system. Chest 1986; 90:476-479
43. 43 Irwin DH, Kaplan LD. Pulmonary manifestations of acquired immunodeficiency syndrome-associated malignancies. Semin Respir Infect 1993; 8:139-148
44. 44 Fouret PJ, Touboul JL, Maynaud CM, et al. Pulmonary Kaposi's sarcoma in patients with acquired immunodeficiency syndrome: a clinicopathological study. Thorax 1987; 42:262-268
45. 45 Huang L, Schnapp LM, Gruden JF, et al. Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Am J Respir Crit Care Med 1996; 153:1385-1390
46. 46 Northfelt DW. AIDS-related Kaposi's sarcoma: still a problem, still an opportunity. J Clin Oncol 1994; 12:1109-1110
47. 47 Young B, Johnson S, Bahktiari M, et al. Resistance mutations in protease and reverse transcriptase genes of HIV-1 isolates from patients failing combination antiretroviral therapy. J Infect Dis 1998; 178:1497-1501
48. 48 Nickoloff BJ, Griffiths CE. The spindle-shaped cells in cutaneous Kaposi's sarcoma: histologic simulators include factor XIIIa dermal dendrocytes. Am J Pathol 1989; 135: 793-800
49. 49 McNutt NS, Fletcher V, Conant MA. Early lesions of Kaposi's sarcoma in homosexual men: an ultrastructural comparison with other vascular proliferations in skin. Am J Pathol 1983; 111:62-77
50. 50 Zhang YM, Bachmann S, Hemmer G, et al. Vascular origin of Kaposi's sarcoma: expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor. Am J Pathol 1994; 144:51-59
51. 51 Kaaya EE, Parravicini C, Ordonez C, et al. Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells and lesions and in culture. J Acquir Defic Syndr Hum Retrovirol 1995; 10:295-305
52. 52 Fiorelli V, Gendelman R, Sirianni MC, et al. Gamma-interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood 1998; 91:956-967
53. 53 Purdy JJ, Colby TV, Yousem SA, et al. Pulmonary Kaposi's sarcoma premortem histologic diagnosis. Am J Surg Pathol 1986; 10:301-311
54. 54 Case records of the Massachusetts General Hospital: weekly clinicopathologic exercises. A 29-year-old man with a positive test for HIV and reticulonodular pulmonary infiltrate: case 1-1990. N Engl J Med 1990; 322:43-51
55. 55 Nash G, Fligiel S. Kaposi's sarcoma presenting as pulmonary disease in the acquired immunodeficiency syndrome: diagnosis by lung biopsy. Hum Pathol 1984; 15:999-1001
56. 56 Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. A 36-year-old man with AIDS and respiratory failure: case 34-1993. N Engl J Med 1993; 329:645-653
57. 57 Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science 1988; 242:426-430
58. 58 Gallo RC. The enigmas of Kaposi's Sarcoma. Science 1998; 282:1837-1839
59. 59 Ensoli B, Gallo RC. AIDS-associated Kaposi's sarcoma: a new perspective of its pathogenesis and treatment. Proc Assoc Am Phys 1995; 107:8-18
60. 60 Kelly GD, Ensoli B, Gunthel CJ, et al. Purified Tat induces inflammatory response genes in Kaposi's sarcoma. AIDS 1998; 12:1753-1761
61. 61 Miles SA. Pathogenesis of AIDS-related Kaposi's sarcoma: evidence of a viral etiology. Hematol Oncol Clin North Am 1996; 10:1011-1021
62. 62 Jung-Chung L. Kaposi's sarcoma and HHV-8: implications for therapy. Infect Med 1998; 15:337-343
63. 63 Barillari G, Gendelman R, Gallo RC, et al. The Tat protein of human immunodeficiency virus type I, a growth factor for AIDS Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90:7941-7945
64. 64 Ensoli G, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989; 243:223-226
65. 65 Cornali E, Zeitz C, Benelli R, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996; 149:1851-1869
66. 66 Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674-680
67. 67 Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997; 336:988-993
68. 68 Vecini S, Sirianni MC, Vincenzi L, et al. Kaposi's sarcoma cells express the macrophage-associated antigen mannose receptor and develop in peripheral blood cultures of Kaposi's sarcoma patients. Am J Pathol 1997; 150:929-937
69. 69 Barkin C, Janz S, Pack S, et al. Genetic abnormalities in Kaposi's sarcoma tumors. Abstract 22284. Presented at 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland
70. 70 Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J Virol 1996; 70:549-558
71. 71 Sarid R, Sato T, Bohensky RA, et al. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3:293-298
72. 72 Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptors of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391:86-89
73. 73 Nicholas J, Ruvolo VR, Burns WH, et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 1997; 3:287-292
74. 74 Sirianni M, Vincenzi L, Fiorelli V, et al. Gamma-interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood 1998; 91:968-976
75. 75 Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA 1990; 263:402-406
76. 76 Payne SF, Lemp GF, Rutherford GW. Survival following diagnosis of oral Kaposi's sarcoma for AIDS patients in San Francisco. J Acquir Immune Defic Syndr 1990; 3:S14-S17
77. 77 Miles SA, Wang H, Elashoff R, et al. Improved survival for patients with AIDS-related Kaposi's sarcoma. J Clin Oncol 1994; 12:1910-1916
78. 78 Gruden JF, Huang L, Webb WR, et al. AIDS-related Kaposi's sarcoma of the lung: radiographic findings and staging system with bronchoscopic correlation. Radiology 1995; 195:545-552
79. 79 Fife K, Bower M. Recent insights into the pathogenesis of Kaposi's sarcoma. Br J Cancer 1996; 73:1317-1322
80. 80 Mocroft AJ, Lundgren JD, d'Armino Monforte A, et al. Survival of AIDS patients according to the type of AIDS-defining event: the AIDS in Europe Study Group. Int J Epidemiol 1997; 26:400-407
81. 81 Zwhalen M, Neunschwander BE, Vlahor D, et al. Using registry data to estimate trends in survival after AIDS diagnosis in Switzerland, diagnosed between 1988 and 1992. Abstract 60253. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland
82. 82 Brodt HR, Kamps BS, Helm EB, et al. Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS 1998; 12:1475-1481
83. 83 Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7:1201-1207
84. 84 Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification: AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085-3092
85. 85 Couderc LJ, Detruchis P, Mathern S, et al. Pulmonary Kaposi's sarcoma (KS) in patients with HIV infection [abstract 2091]. Int Conf AIDS 1990; 6:376
86. 86 Pozniak A, Latif A, McLead D, et al. Clinical, radiological, and bronchoscopic features of pulmonary Kaposi's sarcoma [abstract 2099]. Int Conf AIDS 1990; 6:378
87. 87 Tupule A, Yung RC, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 1998; 16:3369-3374
88. 88 Meyer JL. Whole-lung irradiation for Kaposi's sarcoma. Am J Clin Oncol 1993; 16:372-376
89. 89 Aboulafia DM, Olson M, Bundow D. Clinical characteristics of advanced pulmonary KS (PKS): a difficult disease to treat [abstract 53]; Third National AIDS Malignancy Conference. J Acquir Immune Defic Syndr 1999; 21:A23
90. 90 Kanter A, Spencer DC, Steinberg MH. Incidence and characteristics of HIV-related conditions in distinct South Africa populations. Abstract 13381. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland. Abstract 13381.
91. 91 Pozniak AL, Latif AS, Neill P, et al. Pulmonary Kaposi's sarcoma in Africa. Thorax 1992; 47:730-733
92. 92 Kaplan LD, Hopewell PC, Jaffe H, et al. Kaposi's sarcoma involving the lung in patients with acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988; 1:23-30
93. 93 Stansel JD, Murray JF. Pulmonary complications of human immunodeficiency virus infection. In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine. 2nd ed. Philadelphia, PA: W. B. Saunders, 1996
94. 94 Jeyapalan M, Steffenson S. Diagnosis of pulmonary Kaposi's sarcoma in AIDS patients. AIDS Patient Care STDs 1997; 11:9-12
95. 95 Kornfield H, Axelrod JL. Pulmonary presentation of Kaposi's sarcoma in a homosexual patient. Am Rev Respir Dis 1983; 127:248-249
96. 96 Roux FJ, Bancal C, Dombret MC, et al. Pulmonary Kaposi's sarcoma revealed by a solitary nodule in a patient with acquired immunodeficiency syndrome. Am J Respir Crit Care Med 1994; 149:1041-1043
97. 97 Sadaghdar H, Eden E. Pulmonary Kaposi's sarcoma presenting as fulminant respiratory failure. Chest 1991; 100: 858-860
98. 98 Bach MC, Bagwell SP, Fanning JP. Primary pulmonary Kaposi's sarcoma in the acquired immunodeficiency syndrome: a cause of persistent pyrexia. Am J Med 1988; 85:274-275
99. 99 McGuinness G. Changing trends in the pulmonary manifestation of AIDS. Radiol Clin North Am 1997; 35:1029-1082
100. 100 Denton AS, Miller RF, Spittle MF. Management of pulmonary Kaposi's sarcoma: new perspectives. Br J Hosp Med 1995; 53:344-350
101. 101 Hartman TE, Primack SL, Müller NL, et al. Diagnosis of thoracic complications in AIDS: accuracy of CT. AJR Am J Roentgenol 1994; 162:547-553
102. 102 Khalil AM, Carette MR, Cadranel JL, et al. Intrathoracic Kaposi's sarcoma: CT findings. Chest 1995; 108:1622-1626/ Eur Respir J 1994; 7:1285-1289
103. 102 Khalil AM, Carette MR, Cadranel JL, et al. IntrathoracicKaposi's sarcoma: CT findings. Chest 1995; 108:1622-1626/ Eur Respir J 1994; 7:1285-1289
104. 103 Sivit CJ, Schwartz AM, Rockoff SD. Kaposi's sarcoma of the lung in AIDS: radiologic-pathologic analyses. AJR Am J Roentgenol 1987; 145:25-28
105. 104 Wolff SD, Kuhlman JE, Fishman EK. Thoracic Kaposi's sarcoma in AIDS: CT findings. J Comput Assist Tomogr 1993; 17:60-62
106. 105 Kang EY, Staples CA, McGuinness G, et al. Detection and differential diagnosis of pulmonary infections and tumors in patients with AIDS: value of chest radiography versus CT. AJR Am J Roentgenol 1996; 1:15-19
107. 106 Kirshenbaum KJ, Burke R, Fanapour F, et al. Pulmonary high-resolution computed tomography versus gallium scintigraphy: diagnostic utility in the diagnosis of patients with AIDS who have chest symptoms and normal or equivocal chest radiographs. J Thorac Imaging 1998; 13:52-57
108. 107 Lee VW, Fuller JD, O'Brien MJ, et al. Pulmonary Kaposi's sarcoma in patients with AIDS: scintigraphic diagnosis with sequential thallium and gallium scanning. Radiology 1991; 180:409-412
109. 108 Delval Gomez MA, Castro Beiras JM, Gallardo FG, et al. Thallium and gallium scintigraphy in pulmonary Kaposi's sarcoma in an HIV-positive patient. Clin Nucl Med 1994; 19:467-468
110. 109 Buscombe JR, Oyen WJ, Grant A, et al. Indium-111-labeled polyclonal human immunoglobulin: identifying focal infection in patients positive for human immunodeficiency virus. J Nucl Med 1993; 34:1621-1625
111. 110 Khalil AM, Carette MF, Cadranel JL, et al. Magnetic resonance imaging findings in pulmonary Kaposi's sarcoma: a series of 10 cases. Eur Respir J 1994; 7:1285-1289
112. 111 Hamm PG, Judson MA, Aranda CP. Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy: a report of five cases. Cancer 1987; 59:807-810
113. 112 Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 1994; 105:1314-1323
114. 113 Afessa B, Green W, Chiao J, et al. Pulmonary complications of HIV infection: autopsy findings. Chest 1998; 113:1225-1229
115. 114 Zibrak JD, Silvestri RC, Costello P, et al. Bronchoscopic and radiologic features of Kaposi's sarcoma involving the respiratory system. Chest 1986; 90:476-479
116. 115 Broderick PA, Krinsley JS. Pulmonary Kaposi's disease diagnosis by transbronchial biopsy. Conn Med 1990; 54:555-557
117. 116 Hughes-Davies L, Kocjan G, Spittle MF, et al. Occult alveolar hemorrhage in bronchopulmonary Kaposi's sarcoma. J Clin Pathol 1992; 45:536-537
118. 117 Hill ADK, Darzi A, Menzies-Gow N, et al. Thorascopic biopsy in the diagnosis of pulmonary Kaposi's sarcoma. J Laparoendosc Surg 1993; 3:571-572
119. 118 Foreman KE, Bacon PE, Hsi ED, et al. In situ polymerase chain reaction-based localization studies support role of human herpesvirus-8 as the cause of two AIDS-related neoplasms: Kaposi's sarcoma and body cavity lymphoma. J Clin Invest 1997; 99:2971-2978
120. 119 Benfield TL, Dodt KK, Lundgren JD. Human herpes virus-8 DNA in bronchoalveolar lavage samples from patients with AIDS-associated pulmonary Kaposi's sarcoma. Scand J Infect Dis 1997; 29:13-16
121. 120 Nasti G, Errante D, Santarossa S, et al. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Saf 1999; 20:403-425
122. 121 Von Roenn J, Krown SE, Benson CA, et al. Management of AIDS-associated Kaposi's sarcoma: a multidisciplinary perspective Oncology (Huntingt)1998; 12(Suppl 3):9-24
123. 122 Sloand E, Kumar PN, Pierce PF. Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of Filagrastin (G-CSF) in supporting dose administration. South Med J 1993; 86:1219-1224
124. 123 Gabizon A, Catane R Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-992
125. 124 Northfelt DW. Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma. Oncology 1997; 11(suppl 11):21-32
126. 125 Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353-2364
127. 126 Northfelt DW, Dezube BJ, Thommes JA, et al. Peglytedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445-2451
128. 127 Cabriales S, Bresnahan J, Testa D, et al. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases. Oncol Nurs Forum 1998; 25:67-70
129. 128 Saville MW. Epidemic Kaposi's sarcoma [editorial]. Oncology 1998; 12:1390-1391
130. 129 Bennett CL, Golub RM, Stinson TJ, et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:460-465
131. 130 Schurmann D, Dormann A, Grunewald T, Ruf B. Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin. Eur Respir J 1994; 7:824-825
132. 131 Saint-Marc T, Jeanblanc F, Makhloufi D, et al. Phase II clinical trial of liposomal daunorubicin in the treatment of pulmonary Kaposi's sarcoma [abstract 2219]. Int Conf AIDS 1996; 11:303
133. 132 Grunaug M, Bogner JR, Loch O, et al. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. International Conference on AIDS. Eur J Med Res 1998; 3:13-19
134. 133 Mitsuyasu R, von Roen J, Krown S, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's sarcoma (AIDS-KS): AIDS clinical trials group (ACTG) protocol 286 [abstract 191]. Proc Am Soc Clin Oncol Annu Meet 1997; 16:55A
135. 134 Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998; 16:1112-1121
136. 135 Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999; 17:1876-1883
137. 136 Cohen L. Dose, time and volume parameters in irradiation therapy of Kaposi's sarcoma. Br J Radiol 1962; 35:485-488
138. 137 Nobler MP. Pulmonary irradiation for Kaposi's sarcoma. Am J Clin Oncol 1985; 8:441-444
139. 138 Berson AM, Quivey JM, Harris JW, Wara WM. Radiation therapy for AIDS-related Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1990; 19:569-575
140. 139 Doyle M, Johnstone PA, Watkins EB. Role of radiation therapy in management of pulmonary Kaposi's sarcoma. South Med J 1993; 86:285-288
141. 140 Leigh BR, Lau DH. Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus. a case report and review of the literature. Am J Clin Oncol 1998; 21:479-481
142. 141 Swift PS. The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996; 10:1069-1080
143. 142 Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334:1011-1017
144. 143 Gullick R, Squires K, Powderly W, et al. An open-label, randomized comparative study of Stavudine + lamivudine + indinavir in treatment naive HIV-infected subjects. Abstract 12223. Presented at: 12th World AIDS Conference; June 26-July 3, 1998; Geneva, Switzerland.
145. 144 Update trends in AIDS incidence, deaths, and prevalence: United States 1996. MMWR Morb Mortal Wkly Rep 1997; 46:165-173
146. 145 Palella FJ Jr, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med 1998; 338:853-860
147. 146 Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter]. JAMA 1997; 277:1519-1520
148. 147 Power C, Nath A, Aoki FY, et al. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection [letter]. N Engl J Med 1997; 336:661-662
149. 148 Call A, Foudraine N, Reiss P, et al. Resolution of antibiotic-resistant cryptosporidiosis (C) and microsporidiosis (M) with potent combination antiretroviral therapy [abstract]. Fourth Conf Retroviruses Opportun Infect 1997; 4:191
150. 149 Peters PS. What does HIV teach us about cancer [editorial]. Clin Oncol (R Coll Radiol) 1997; 9:355-356
151. 150 Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998; 73:439-443
152. 151 Volm MD, Wenz J. Patients with advanced AIDS-related Kaposi's sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy [abstract]. Proc Am Soc Clin Oncol Annu Meet 1997; 16:A162
153. 152 Santambrogio S, Ridolfo AL, Galli TM, et al. Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated KS. Abstract 22275. Presented at: 12th World AIDS Conference; 1998; Geneva, Switzerland
154. 153 Bower M, Fox P, Fife K, et al. HAART prolongs time to treatment failure (TTF) in Kaposi's sarcoma (KS) [abstract 58]. Third National AIDS Malignancy Conference. J Acquir Immune Defic Syndr 1999; 21:A24
155. 154 Chanan-Khan, Goldman M, Volm C, et al. Patients with AIDS-related pulmonary Kaposi's sarcoma (PKS) treated with highly active antiretroviral therapy (HAART) alone after induction with systemic chemotherapy [abstract 59]. Third National AIDS Malignancy Conference. J Acquir Immune Defic Syndr 1999; 21:A24
156. 155 Ganem D. KSHV/HHV8 infection and the pathogenesis of AIDS-related neoplasms: an overview [abstract S7]. Third National AIDS Malignancy Conference. J Acquir Immune Defic Syndr 1999; 21:A8
157. 156 Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 78:70-79
158. 157 Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-F14
159. 158 Young B, Johnson S, Bahktiari M, et al. Resistance mutations in protease and reverse transcriptase genes of HIV-1 isolates from patients failing combination antiretroviral therapy. J Infect Dis 1998; 178:1497-1501
160. 159 Furtado MR, Callaway DS, Phair JP, et al. Resistance of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-1622
161. 160 Desrosiers RC. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med 1999; 5:723-725